23rd International Workshop on Kaposi's Sarcoma Herpesvirus (KSHV) and Related Agents

摘要 本会议拨款申请申请资金，以帮助支持第23届国际会议 2020年卡波西肉瘤疱疹病毒及相关药物会议。我们一年一度的 会议将汇集研究致癌人类的研究人员和临床医生 疱疹病毒、卡波西氏肉瘤疱疹病毒(KSHV)和其他密切相关的病原体。KSHV 是卡波西氏肉瘤(KS)的病原体，KS仍然是全世界最常见的癌症之一 非洲，特别是艾滋病毒-1感染者。这笔资金将用于减少会议规模 优秀博士后和博士后实习生的注册费用历来偏低 少数民族和来自低收入国家的科学家，特别是那些来自非洲的研究人员 致癌DNA病毒和与这些病毒相关的癌症。这些项目的目标是 会议与NIH、NCI、NIAID和NIDCR的任务声明一致，即， 推进和促进人类癌症相关感染的研究步伐，并 其他疾病，包括艾滋病毒-艾滋病背景下的疾病。KSHV主要会议将在#年举行 坦桑尼亚达累斯萨拉姆，2020年6月22日下午至6月25日。带着一个 额外的一天，6月26日，用于培训研讨会，以吸引知名研究人员和 实习生、临床医生和基础研究人员，在翻译方面进行互动和合作 研究项目。会议的所有剩余费用将从已支付的注册费中筹集。 由与会者和主办机构、基金会和制药及 生物技术公司。KSHV会议的主要焦点是致癌生物学 疱疹病毒和相关的人类疾病，特别强调病毒的发病机制， 病毒潜伏期和重新激活，病毒基因表达和复制，宿主对感染的反应， 流行病学、疫苗开发、治疗干预、临床和转译研究。 除KSHV外，与疱疹病毒塞米里(HVS)、小鼠疱疹病毒-68(MHV-68)相关的研究 68)，并将介绍恒河猴流感病毒(RRV)。第23届中国国际会议 卡波西的肉瘤-疱疹病毒和相关药物将标志着新的四分之一世纪的研究 关于KSHV自1994年发现这种病毒以来，进入了一个新的世纪，让临床医生和 来自感染KSHV及其相关恶性肿瘤的大陆的研究人员 世界最高峰

Abstract This conference grant application requests funds to help support the 23nd International Conference on Kaposi's Sarcoma Herpesvirus and Related Agents in 2020. Our annual conference will bring together researchers and clinicians working on the oncogenic human herpesvirus, Kaposi's sarcoma herpesvirus (KSHV), and other closely related pathogens. KSHV is the etiology agent of Kaposi's sarcoma (KS), which is still one of the most prevalent cancers in Africa, especially in HIV-1 infected individuals. The funds will be used to reduce the conference registration costs for outstanding pre- and post-doctoral trainees, historically under-represented minorities, and scientists from lower income countries, especially those from Africa who study oncogenic DNA viruses and the cancers associating with these viruses. The goals of these meetings are consistent with the mission statements of the NIH, NCI, NIAID, and NIDCR, namely, to advance and promote the pace of research on infections associated with human cancer and other diseases, including in the setting of HIV-AIDS. The main KSHV conference will be held in Dar es Salaam, Tanzania, from the afternoon of June 22 through June 25, 2020. With an additional day, June 26, for a training workshop to engage both established researchers and trainees, clinicians and basic researchers, to interact and develop collaborations on translational research projects. All remaining costs for the conference will be raised from registration fees paid by the conferees and contributions from host institutions, foundations, and pharmaceutical and biotechnology companies. The major focus of the KSHV meeting is the biology of oncogenic herpesviruses and associated human diseases, with specific emphasis on viral pathogenesis, viral latency and reactivation, viral gene expression and replication, host responses to infection, epidemiology, vaccine development, therapeutic intervention, clinical and translational research. In addition to KSHV, studies related to herpesvirus saimiri (HVS), murine herpesvirus-68 (MHV- 68), and rhesus rhadinovirus (RRV) will be presented. The 23nd International Conference on Kaposi's Sarcoma- Herpesvirus and Related Agents will mark a new quarter century of research on KSHV since the discovery of this virus in 1994, a new century to engage clinicians and researcher from the continent where infection by KSHV and its associated malignancy is the highest in the world